• Home Blog Nutritional disorders and weight loss

Nutritional Disorders and Weight Loss

pharma-news-for-novo-telix-beacon

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Novo’s CagriSema Shows Greater Weight Loss Than Tirzepatide in REIMAGINE 5 Trial; Telix and ITM Partner to Build a Radiopharmaceutical Powerhouse; Beacon Therapeutics Reveals Positive Topline Findings from VISTA Trial of Laru-zova for XLRP; FDA Clears Inluriyo in Combination with Verzenio for Adults with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer; IntraBio Announces FDA Approval of AQNEURSA for Ataxia-Telangiectasia

Explore More...
obesity-drugs-by-revenue

Top Obesity Drugs by Revenue in 2025: The Biggest Winners in the Weight Loss Market

dietary-supplements-market-assessment

Nutrition Nexus: Illuminating the Growth Trajectory Path in the Dietary Supplements Market

oral-glp-1s-in-obesity-treatment

The Oral GLP-1 Revolution: How Pill-Based Drugs Are Reshaping the Obesity Treatment Space

Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

pharma-news-for-novo-windward-astrazeneca

Novo Nordisk Gains US Approval for Oral WEGOVY; Windward Bio Strengthens Immunology Pipeline With Clinical-Stage Bispecific WIN027; US FDA Grants Breakthrough Therapy Designation to ENHERTU in the Post-neoadjuvant Setting for HER2-positive Early Breast Cancer; Ipsen Enhances Early R&D Pipeline via Simcere Zaiming ADC; Roche Secures FDA Approval for SC Lunsumio VELO in Follicular Lymphoma

pharma-news-for-novo-astrazeneca-cytokinetics

Novo Nordisk Seeks FDA Approval for CagriSema; EU Approves Subcutaneous Self-administration of SAPHNELO via Pre-filled Pen for SLE; Cytokinetics Secures FDA Approval of MYQORZO for Adult Patients with Symptomatic Obstructive HCM; Boehringer’s JASCAYD Wins FDA Approval for Adult Pulmonary Fibrosis; BioMarin to Acquire Amicus for $4.8B, Advancing Long-Term Growth in Rare Diseases

novo-metsera-acquisition

Pharma Rivalry Intensifies: Novo Nordisk Looks to Wrest Metsera from Pfizer

semaglutide-phase-iiib-step-up-program

STEP UP: A Powerful Leap Forward for WEGOVY (semaglutide) in the Obesity Market

eloralintide-phase-i-data

Eloralintide: A Promising Amylin Analog Positioned for the Next Wave of Obesity Therapies

wve-007-inlight-phase-i-trial

siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile

How Robots Are Introducing A New Dimension To Healthcare Service Delivery

How Robots Are Introducing A New Dimension To Healthcare Service Delivery

7-obesity-drugs-launches

9 Promising Obesity Drugs Set to Launch by 2030

The Obesity Pandemic What can we do about it

The Obesity Pandemic: What Can we do About it?

An Insight Into the Weight Loss and Obesity Market

An Insight Into the Weight Loss and Obesity Market

novo-vs-eli-lilly-in-anti-obesity-drug-market

Novo Nordisk vs. Eli Lilly: The Battle for Anti-Obesity Drug Market Dominance

emerging-therapies-for-obesity-treatment

Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader